KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Leases (2016 - 2017)

Historic Capital Leases for Nektar Therapeutics (NKTR) over the last 8 years, with Q3 2017 value amounting to $3.0 million.

  • Nektar Therapeutics' Capital Leases fell 3333.33% to $3.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $3.0 million, marking a year-over-year decrease of 3333.33%. This contributed to the annual value of $2.2 million for FY2016, which is 10717.61% up from last year.
  • Per Nektar Therapeutics' latest filing, its Capital Leases stood at $3.0 million for Q3 2017, which was down 3333.33% from $3.8 million recorded in Q2 2017.
  • Nektar Therapeutics' 5-year Capital Leases high stood at $10.8 million for Q1 2013, and its period low was $1.1 million during Q4 2015.
  • Its 5-year average for Capital Leases is $6.3 million, with a median of $6.4 million in 2016.
  • In the last 5 years, Nektar Therapeutics' Capital Leases plummeted by 7407.59% in 2015 and then soared by 10717.61% in 2016.
  • Nektar Therapeutics' Capital Leases (Quarter) stood at $8.0 million in 2013, then crashed by 48.58% to $4.1 million in 2014, then crashed by 74.08% to $1.1 million in 2015, then skyrocketed by 107.18% to $2.2 million in 2016, then surged by 34.95% to $3.0 million in 2017.
  • Its Capital Leases was $3.0 million in Q3 2017, compared to $3.8 million in Q2 2017 and $4.5 million in Q1 2017.